Protocols: Editas adds CRISPR/Cas9 IP; biosimilars make fresh gains in U.S. market
Editas $EDIT has picked up some fresh CRISPR/Cas9 IP from Mass General. The gene editing pioneer, which has focused on adding fresh tech in the race to get programs into the clinic, says the deal adds “high-fidelity Cas9 nucleases and Cas9 PAM variants that will enable the Company to address an expanded range of genetically-defined diseases with the potential for enhanced specificity.”
Anyone looking for fresh evidence of the impact biosimilars will have on branded drugs should look to the latest news from CVS, which just replaced Sanofi’s Lantus with a cheaper copycat from Eli Lilly on its formulary. Drug buyers will have little trouble forcing patients to take less expensive biosimilars in the U.S., which will help accelerate rapid adoption.
The private equity group Velocity Fund Partners has acquired the Philadelphia-based CRO Indipharm and relaunched it as InClinica.